CELG Celgene Corporation

143.47
+0.63  (0%)
Previous Close 142.84
Open 142.93
Price To book 13.30
Market Cap 112243850912
Shares 782,350,672
Volume 2,982,391
Short Ratio 2.85
Av. Daily Volume 3,375,819

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals
  2. 8-K - Current report 171044240
  3. 8-K - Current report 171020773
  4. 424B2 - Prospectus [Rule 424(b)(2)] 17999570
  5. 424B2 - Prospectus [Rule 424(b)(2)] 17998124

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2018.
Luspatercept - COMMANDS
Myelodysplastic syndromes (MDS) cancer - first-line
Phase 3 trial to be initiated 2017.
OTEZLA
Ankylosing Spondylitis
Phase 3 to be initiated 2017.
RPC-4046
Eosinophilic Esophagitis (EoE)
Phase 3 trial initiated 1Q 2017 - not yet enrolling as of April 2017.
OTEZLA
Scalp Psoriasis
Phase 3 data due 2018.
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 3 data released at ASH 2016.
REVLIMID - REMARC
Maintenance in Patients with Diffuse large B-cell lymphoma (DLBCL) responding to R-CHOP to induction therapy
Phase 3 data due 2H 2017.
REVLIMID - RELEVANCE
Newly Diagnosed Follicular Lymphoma
Phase 3 data released at ASH December 2016.
REVLIMID - MYELOMA XI
Induction and Maintenance in ASCT Eligible
Phase 3 data due 2019.
REVLIMID - MAGNIFY NHL-010
Untreated Activated B-Cell Diffuse large B-cell lymphoma (DLBCL)
Phase 3 enrollment complete - noted April 27, 2017.
REVLIMID - MM-026 ARUMM
Multiple Myeloma - Maintenance Post-VMP induction
Phase 3 data released at ASH 2016.
REVLIMID - CLL-002 CONTINUUM
Maintenance in Second-line Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due 2020.
REVLIMID - MAGNIFY NHL-008
Relapsed or Refractory Indolent Lymphoma
Phase 3 data due 2018.
MM-007 OPTIMISMM
Multiple Myeloma - refractory
Phase 3 data due 2H 2017.
REVLIMID - AUGMENT NHL-007
Relapsed or Refractory Follicular Lymphoma
Phase 3 enrolling. Data due 2018.
Ozanimod - TRUE NORTH
Ulcerative Colitis
Phase 3 data released February 17, 2017 - primary endpoint met. Full data 2H 2017.
Ozanimod - SUNBEAM
Relapsing Multiple Sclerosis
Phase 3 - primary endpoint met.
OTEZLA - PSA-006
Psoriatic Arthritis
sNDA filing due 2017
OTEZLA
Once daily formulation
Phase 3 data due 2017.
OTEZLA - BCT-002 RELIEF
Behçet’s Disease
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
Luspatercept - BELIEVE
b -thalassemia
Phase 3 enrollment completion announced June 1, 2017 with data due mid-2018.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 enrolling. Data due 2018.
GED-0301 (CD-003)
Crohn’s disease
Phase 3 enrolling. Data due 2018.
GED-0301 (CD-002)
Crohn’s disease
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of April 2017.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Phase 3 data due 2018.
Oral Azacitidine - CC-486-AML-001
Post induction AML Maintenance
Phase 3 data due 2H 2017.
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 enrolling.
CC-486 (Oral Azacitidine)
Low risk/INT-1 transfusion-dependent MDS
Phase data due 2017.
ABRAXANE - NSCL-003 abound.sqm
First-line late stage Squamous Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2017.
ABRAXANE - NSCL-003 abound.70+
Elderly Non-small cell lung cancer (NSCLC)
Phase 3 enrolling.
ABRAXANE - NSCL-003
Maintenance After Induction in Squamous Non- Small Cell Lung Cancer
Phase 3 data due 2018.
ABRAXANE - IMpower 131 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2018.
ABRAXANE - IMpower 130 ( I/O Combo)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2018.
ABRAXANE - IMPassion ( I/O Combo)
Triple Negative Metastatic Breast Cancer
Phase 3 data due released May 22, 2017 - primary endpoint met, disability endpoint not met. Full data due 2H 2017.
Ozanimod - RADIANCE
Relapsing Multiple Sclerosis
Phase 2 data due 2H 2017. Phase 3 trial to be initiated 2018.
OTEZLA
Ulcerative Colitis
Phase 2 enrollment to commence 2017.
Luspatercept
Myelofibrosis
Phase 2 data due 2H 2017.
GED-0301
Ulcerative Colitis
Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 3 trial planned for 2H 2017.
Marizomib
Glioblastoma (GBM) cancer
Pivotal trial to be initiated in 2017. ASCO Poster Session June 5, 2017 - ORR 86%.
JCAR017
Relapsed/refractory B cell non-Hodgkin lymphoma - cancer
Phase 1/2 MM trials placed on clinical hold - September 7, 2017. AML/MDS trials to continue.
Durvalumab - FUSION
Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML
Phase 1/2 trials ongoing. Data from MM trial due 2H 2017.
CC-122
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM)
Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017 - ORR 89%. Pivotal trial to be initiated by the end of 2017.
bb2121
Relapsed/refractory multiple myeloma
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Relapsed/Refractory IDH2 mutant-positive Acute Myeloid Leukemia -
Approved February 22, 2017.
REVLIMID
Multiple myeloma (MM) - autologous stem cell transplant (ASCT)